Description
Latin name
Dona
Release form
Intramuscular solution 200 mg / ml. 2 ml in ampoules A of transparent light-protective glass, type 1, ampoules have a white ring, indicating the place of breaking of ampoules.
Solvent. 1 ml in ampoules B of transparent colorless glass, type 1, ampoules have a white ring indicating the place of breaking of the ampoules.
6 ampoules A in a PVC tablet and 6 ampoules B (solvent) in a PVC tablet are placed together with instructions for use in a cardboard box.
Pharmacological action of
Pharmacological properties of
DONA – has anti-inflammatory and analgesic effects, replenishes endogenous glucosamine deficiency, stimulates the synthesis of proteoglycans and hyaluronic acid in synovial fluid, increases the permeability of the joint capsule, and restores the enzymatic and cellular membranes in the joint. It promotes the fixation of sulfur during the synthesis of chondroitin sulfuric acid, facilitates the normal deposition of calcium in bone tissue, inhibits the development of degenerative processes in the joints, restores their function, reducing joint pain.
Pharmacokinetics
When administered intramuscularly, the bioavailability of 95%, spreads rapidly in the tissues, the elimination half-life of about 60 hours, is excreted mainly by the kidneys.
Indications
Primary and secondary osteoarthritis, osteochondrosis, spondylarthrosis.
Contraindications
Individual hypersensitivity to glucosamine, lidocaine hydrochloride and other components of the drug. Due to the presence of lidocaine in the composition of the product, it is contraindicated in patients with cardiac conduction disorders and acute heart failure, history of epileptiform seizures, severe liver and kidney dysfunctions during pregnancy and lactation, as well as in children under 12 years old.
Special instructions
Caution should be used in patients with chronic heart failure, hypotension. Caution should be exercised in patients with allergies to seafood (shrimp, shellfish).
When using the drug in patients with impaired glucose tolerance, with severe hepatic and renal failure, medical supervision is necessary.
Composition
Solution A: each ampoule (2 ml) contains:
active substance: crystalline glucosamine sulfate 502.5 mg (contains 400 mg glucosamine sulfate and 102.5 mg sodium chloride)
excipients: lidocaine hydrochloride 10.0 mg water for injection up to 2 ml.
Solution B: Ampoule (1 ml) contains:
excipients: diethanolamine – 24.0 mg, water for injection up to 1 ml.
Dosage and administration of
Intramuscularly!
The drug is not intended for intravenous administration.
Before use, mix solution B (solvent) with solution A (drug solution) in one syringe. The prepared solution of the drug is administered intramuscularly in 3 ml (solutions A + B) 3 times a week for 4-6 weeks.
Injection of the drug can be combined with oral administration of the drug in powder to prepare an oral solution (sachets). The duration and treatment regimen is prescribed by the attending physician.
Side effects
Drug tolerance is good. In some cases, possible: flatulence, diarrhea, constipation, allergic reactions – urticaria, itching. Due to the content of lidocaine in the preparation, nausea, vomiting, drowsiness, diplopia, headache, dizziness, numbness of the tongue and oral mucosa, tremors, euphoria, disorientation, and cardiac conduction are possible.
Drug Interactions
Compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids.
Caution should be exercised when administering the drug in combination with beta-blockers, digitoxin, aymalin, amiodarone, verapamil, quinidine, novocainamide, hexenal or thiopental sodium, MAO inhibitors, polymyxin-B, hypnotics or sedatives, cimetidine.
Overdose
No cases of overdose.
Storage conditions
At a temperature not exceeding 25 ° C. Keep out of the reach and sight of children.
Expiration
2 years. Do not use after the expiry date stated on the pack.
Terms leave through pharmacies
In retseptu
Dosage form
solution for injection
